| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_73c4bedd7e22431942942d2572577ed2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f4f8755c361b70eb6af66fd6a114e590
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-70 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2018-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18a3a31ebe44a6e8c751d6bbf2b91f6b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e24163da5b1564511b224dfaae8b5488
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4754184ec9a2bc319d476e29850e076 |
| publicationDate |
2021-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10927170-B2 |
| titleOfInvention |
Anti-claudin 1 monoclonal antibodies for the prevention and treatment of hepatocellular carcinoma |
| abstract |
Use of anti-Claudin 1 monoclonal antibodies and pharmaceutical compositions thereof, for the prevention and/or treatment of hepatocellular carcinoma in patients suffering from liver disease, in particular liver disease that is not associated with HCV infection or in patients who have been cured from HCV infection. Methods of preventing and/or treating hepatocellular carcinoma by administration of such a monoclonal antibody, or a pharmaceutical composition thereof, are also described. Experimental results with the hepatocarcinoma cell line HuH-7.5.1 are given. |
| priorityDate |
2015-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |